http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2314271-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65583 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65128 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6512 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6558 |
| filingDate | 2003-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b339964c4c59cbcaf588cfe856693d4 |
| publicationDate | 2009-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2314271-T3 |
| titleOfInvention | THERAPEUTIC QUINAZOLINE DERIVATIVES. |
| abstract | A compound of the formula (I): (See formula) in which A is a 6-membered heteroaryl containing one nitrogen atom and optionally containing one or two more nitrogen atoms; X is: O, S, S (O), S (O) 2; or NR 14, m is: 0, 1, 2, 3 or 4; Y is a group selected from: O, NR 5 CO, CONR 5, CR 6 R 7 CONR 5 and CR 6 R 7 NR 5; Z is a group selected from: -NR 1 R 2, phosphonoxy, C 3-6 cycloalkyl and C 3-6 cycloalkyl which is substituted by phosphonoxy or C 1-4 alkyl substituted by phosphonoxy and a 4- to 7-membered ring attached by a carbon atom containing a nitrogen atom and optionally containing one more nitrogen atom, a ring that can be saturated, unsaturated or partially saturated, a ring that is substituted on the carbon or nitrogen by phosphonoxy or C1-4 alkyl (substituted by phosphonoxy ) and ring which is optionally further substituted in the carbon or nitrogen by 1, 2 or 3 halo or C1-4 alkyl groups; R 1 is a group selected from: -COR 8, -CONR 8 R 9 and C 1-6 alkyl, C 1-6 alkyl which is substituted by phosphonoxy and optionally further substituted by 1 or 2 halo or methoxy groups; R 2 is a group selected from: hydrogen, -COR 10, -CONR 10 R 11 and C1-6 alkyl, C1-6 alkyl which is optionally substituted by 1, 2 or 3 halo groups or C1-4 alkoxy, -S ( O) pR 11 (where p is 0, 1 or 2) or phosphonoxy or R 2 is a group selected from: C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl and [C3-6 cycloalkyl] C1-4 alkyl ; or R 1 and R 2 together with the nitrogen to which they are attached form a 4- to 7-membered ring that optionally contains one more nitrogen atom, a ring that can be saturated, unsaturated or partially saturated, a ring that is substituted on the carbon or nitrogen by a group selected from phosphonoxy and C1-4 alkyl substituted by phosphonoxy or -NR 8 R 9 and ring which is optionally further substituted on the carbon or nitrogen by 1, 2 or 3 halo groups or C1-4 alkyl; R 3 is a group selected from: hydrogen, halo, cyano, nitro, C 1-6 alkoxy, C 1-6 alkyl, -OR 12, -CHR 12 R 13, -OC (O) R 12, -C (O) R 12, -NR 12 C (O) R 13, -C (O) NR 12 R 13, -NR 12 SO2R 13 and -NR 12 R 13; R 4 is hydrogen or a group selected from: C1-4 alkyl, heteroaryl, heteroaryl [C1-4 alkyl], aryl and aryl [C1-4 alkyl], which group is optionally substituted by 1, 2 or 3 substituents selected from: halo, methyl, ethyl, cyclopropyl and ethynyl; R 5 is a group selected from: hydrogen, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl and [C 3-6 cycloalkyl] C 1-4 alkyl; R 6 and R 7 are independently selected from: hydrogen, halo, C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy and C 1-4 alkoxy; R 8 is C 1-4 alkyl substituted by phosphonoxy and optionally further substituted by 1 or 2 halo or methoxy groups; R 9 is selected from hydrogen and C 1-4 alkyl; R 10 is selected from hydrogen and C 1-4 alkyl, C 1-4 alkyl which is optionally substituted by: halo, C 1-4 alkoxy, S (O) q (where q is 0, 1 or 2) or phosphonoxy; R 11, R 12, R 13 and R 14 are independently selected from: hydrogen, C1-4 alkyl and heterocyclyl or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2002-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 988.